Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine-CWRU, 9500 Euclid Avenue, NC22, Cleveland, OH 44195-0001, USA.
Clin Chest Med. 2012 Sep;33(3):459-71. doi: 10.1016/j.ccm.2012.06.007. Epub 2012 Jul 25.
Diagnosis and treatment of asthma are currently based on assessment of patient symptoms and physiologic tests of airway reactivity. Research over the past decade has identified an array of biochemical and cellular biomarkers, which reflect the heterogeneous and multiple mechanistic pathways that may lead to asthma. These mechanistic biomarkers offer hope for optimal design of therapies targeting the specific pathways that lead to inflammation. This article provides an overview of blood, urine, and airway biomarkers; summarizes the pathologic pathways that they signify; and begins to describe the utility of biomarkers in the future care of patients with asthma.
目前，哮喘的诊断和治疗是基于对患者症状和气道反应性的生理测试评估。过去十年的研究已经确定了一系列生化和细胞生物标志物，这些标志物反映了可能导致哮喘的异质性和多种机制途径。这些机制生物标志物为针对导致炎症的特定途径的治疗提供了最佳设计的希望。本文概述了血液、尿液和气道生物标志物；总结了它们所代表的病理途径；并开始描述生物标志物在未来哮喘患者护理中的应用。
